Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
661.00    -4.00 (-0.60%)
Bid:
660.00
Ask:
662.00
Spread: 2.00 (0.303%)
Market Cap: £538.03m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

6 Jan 2009 08:41

RNS Number : 1619L
Bloomsbury Publishing PLC
06 January 2009
 



 

Bloomsbury Publishing Plc

("Bloomsbury")

Bloomsbury acquires Arden Shakespeare

Bloomsbury Publishing Plc is pleased to announce the acquisition of Arden Shakespeare from Cengage Learning. This transaction is not material to Bloomsbury.

  Arden Shakespeare is the most academically rigorous Shakespeare series in print, and the best-known English literature brand worldwide. Originally created by the British publishing firm of Methuen in the late nineteenth century, and edited by a distinguished collection of scholars, the series took 25 years to complete from the launch of the first title, Edward Dowden's Hamlet, in 1899. In 1995 the Third Series of The Arden Shakespeare was launched. Now published under the imprint Arden Shakespeare, under the General Editorship of Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen, the Arden Shakespeare Third Series is nearing completion. Each new volume supersedes the corresponding Second Series text, being meticulously edited from the original sources by a contemporary scholar.

Arden Shakespeare will retain its internationally recognised name and become part of the Methuen Drama imprint (acquired in 2006 by A&C Black which is a wholly owned subsidiary of Bloomsbury). The acquisition will make Methuen Drama Europe's largest performing arts list, which includes work by Bertolt Brecht, Oscar Wilde, Bernard Shaw and Arthur Miller as well as contemporary playwrights such as Michael Frayn and Willy Russell, Methuen Student editions and the New Mermaids critical editions.

'I am delighted that the Arden Shakespeare series is returning to MethuenArden is a highly prestigious addition to our performing arts publishing and fits perfectly with our strategy of acquiring high quality perennial publishing lists which have significant potential for digital exploitation. We look forward to working with the Arden General Editors Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen to grow and strengthen this important list' says A&C Black Managing Director, Jill Coleman.

Jill Jones, CEO Cengage Learning EMEA said, 'The Arden Shakespeare is an excellent fit for Bloomsbury: we wish A&C Black, all volume editors, authors and General Editors from the Arden Shakespeare success for the future'.

www.methuendrama.com

-ends-

For further enquiries:

Bloomsbury Publishing PLC

Jill Coleman, Bloomsbury Publishing Plc care of Bell Pottinger

Bell Pottinger Corporate & Financial

Ben Woodford / Rosanne Perry +44 (0)20 7861 3232

Notes to Editors

About Bloomsbury Publishing Plc 

(www.bloomsbury.com and www.bloomsbury-ir.co.uk)

Bloomsbury Publishing is one of the world's leading independentpublicly quoted publishing houses with a reputation for a high quality management team and a highly valuable portfolio of intellectual properties including the Encarta World English Dictionary, JK Rowling's Harry Potter, Margaret Atwood, John Irving, David Guterson and Ben Schott. Other databases include Who's Who, Whitaker's AlmanackReed's Nautical Almanac, Black's Medical Dictionary, the Macmillan English Dictionary for Advanced Learners of EnglishBusiness: The Ultimate Resource and RSPB Handbook of British Birds. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUNOWRKKRARRR
Date   Source Headline
3rd Mar 20257:00 amRNSNotice of Trading Update
24th Feb 20254:27 pmRNSHolding(s) in Company
14th Feb 202510:05 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jan 20257:00 amRNSBloomsbury reaches new agreement with Amazon
16th Dec 202410:05 amRNSHolding(s) in Company
16th Dec 20249:55 amRNSHolding(s) in Company - Replacement
11th Dec 202410:24 amRNSDirector/PDMR Shareholding
9th Dec 20249:18 amRNSDirector/PDMR Shareholding
26th Nov 202411:44 amRNSHolding(s) in Company
26th Nov 202410:35 amRNSDirector/PDMR Shareholding
24th Oct 20247:00 amRNSUnaudited Interim Results
30th Sep 20247:00 amRNSNotice of Interim Results
2nd Sep 202411:31 amRNSDirector/PDMR Shareholding
29th Aug 20247:00 amRNSDirector/PDMR Shareholding
28th Aug 202410:57 amRNSDirector/PDMR Shareholding
16th Aug 20244:18 pmRNSAMENDMENT: BLOCK LISTING SIX MONTHLY RETURN
16th Aug 20249:42 amRNSBLOCK LISTING SIX MONTHLY RETURN
7th Aug 20245:36 pmRNSAwards under the 2023 Executive Share Plan
16th Jul 20243:41 pmRNSResults of the 2024 Annual General Meeting
16th Jul 20247:00 amRNSAGM Trading Update
14th Jun 20245:01 pmRNSAnnual Financial Report
14th Jun 20241:48 pmRNSBoard Appointment
29th May 20247:00 amRNSAcquisition
23rd May 20247:00 amRNSChairman Succession Announcement
23rd May 20247:00 amRNSAudited Preliminary Results
20th May 20247:00 amRNSInvestor Presentation
16th Feb 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Feb 20247:00 amRNSTrading Update
1st Feb 20243:11 pmRNSBloomsbury launches latest Sarah J. Maas novel
15th Jan 20247:00 amRNSBloomsbury Appoints Head of Investor Relations
12th Jan 202411:45 amRNSHolding(s) in Company
9th Jan 20244:10 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
15th Nov 20237:00 amRNSBlocklisting Application
31st Oct 20237:00 amRNSInvestor Presentation
26th Oct 20237:00 amRNSUnaudited Interim Results
9th Oct 20231:00 pmRNSBloomsbury playwright Jon Fosse wins Nobel Prize
22nd Sep 20231:26 pmRNSDirector/PDMR Shareholdings - Correction
14th Sep 20237:00 amRNSBloomsbury launches new book by Katherine Rundell
5th Sep 20237:00 amRNSDirector/PDMR Shareholding
1st Sep 20232:05 pmRNSDirector/PDMR Shareholding
30th Aug 20231:56 pmRNSDirector/PDMR Shareholding
29th Aug 20232:11 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20238:00 amRNSBloomsbury enjoys bestseller success
17th Aug 20234:40 pmRNSBLOCK LISTING SIX MONTHLY RETURN
18th Jul 20235:13 pmRNSResults of the 2023 Annual General Meeting
18th Jul 20237:00 amRNSAGM Trading Update
23rd Jun 20232:29 pmRNSAnnual Financial Report
2nd Jun 202311:50 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.